Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Next Previous
X
Search
Trial Profile

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Infliximab; Mycophenolate mofetil
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms MONETTE
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 15 Nov 2024 Planned End Date changed from 30 Jun 2025 to 3 Oct 2025.
    • 27 Jun 2024 Planned End Date changed from 12 Apr 2024 to 30 Jun 2025.
    • 18 Oct 2023 Planned End Date changed from 29 Mar 2024 to 12 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top